Please try another search
Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
Name | Age | Since | Title |
---|---|---|---|
Norio Aikawa | 74 | 2004 | Head of Drug Discovery & Support Business, Head of IP & Legal Department and Director |
Kohichiro Yoshino | 73 | 2003 | CEO, President & Representative Director |
Tsuguo Ogasawara | 84 | 2005 | Independent Outside Director |
Teruo Takayanagi | 77 | 2015 | Independent Outside Director |
Atsuo Arita | 80 | 2004 | Independent Outside Director |
Takao Matsui | - | 2019 | Independent Outside Director |
Emi Yamamoto | 53 | 2015 | GM of Business Mgt., Accounting, HR, General Affairs, CFO, Director & President - CarnaBio USA |
Masaaki Sawa | 53 | 2015 | GM of Research & Development Division, Chief Scientific Officer and Director |
Akinori Arimura | 60 | 2019 | GM of Clinical Development, R&D, Chief Development Officer of CarnaBio USA & Director |
Kaoru Suzuki | - | 2024 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review